Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Netupitant and Palonosetron in Repeated Chemotherapy
NCT01376297Phase 3Completed
- Sponsor
- Helsinn
- Start
- Jul 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Helsinn. Primary endpoint: Percentage of Patients With Adverse Events up to 24 weeks. Started Jul 2011; status: completed.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01376297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01376297.